Eli Lilly employees accept buyout offer
A total of 335 Eli Lilly employees have accepted voluntary buyouts from the drug maker, and their jobs will end June 30.
By Agencies |
INDIANAPOLIS: A total of 335 Eli Lilly and Co employees have accepted voluntary buyouts from the drug maker, and their jobs will end June 30, a spokesman said on Friday.
The employees had until Wednesday to accept the offer. Lilly also will reassign about 150 additional employees to different jobs as it streamlines manufacturing of the insulin products Humalog and Humulin and the osteoporosis drug Forteo.
``It's not a layoff,'' spokesman Phil Belt said. ``They'll be reallocated to other positions at Lilly.''
The company announced last month that it was offering the buyouts, which it called a ``voluntary exit program,'' to about 2,000 employees in central Indiana. Belt said productivity improvements were driving the cuts.
Lilly had planned to cut up to 500 jobs. The company expected about 430 manufacturing employees to take its offer and about 70 people in research and development. The number of employees who accepted the program fell well short of the 500 total, but Belt said that figure was a cap on the cuts, not a goal.
The buyout program included a severance package based on the employees' length of service. Belt declined to offer more details.
Belt said the company will continue to try to improve productivity, but ``there's no formal program like this that's pending or anything.''
The drug maker employs about 12,600 people in central Indiana. Its worldwide employment stood at 40,300 as of March 31, down nearly 13 percent from 46,100 at the end of 2003.
Humalog ranked fourth among Lilly drugs with $1.5 billion (euro0.97 billion) in sales last year. Humulin notched $985 million (euro637.21 million), while Forteo took in $709 million (euro458.66 million).
The employees had until Wednesday to accept the offer. Lilly also will reassign about 150 additional employees to different jobs as it streamlines manufacturing of the insulin products Humalog and Humulin and the osteoporosis drug Forteo.
``It's not a layoff,'' spokesman Phil Belt said. ``They'll be reallocated to other positions at Lilly.''
The company announced last month that it was offering the buyouts, which it called a ``voluntary exit program,'' to about 2,000 employees in central Indiana. Belt said productivity improvements were driving the cuts.
Lilly had planned to cut up to 500 jobs. The company expected about 430 manufacturing employees to take its offer and about 70 people in research and development. The number of employees who accepted the program fell well short of the 500 total, but Belt said that figure was a cap on the cuts, not a goal.
The buyout program included a severance package based on the employees' length of service. Belt declined to offer more details.
ADVERTISEMENT
Belt said the company will continue to try to improve productivity, but ``there's no formal program like this that's pending or anything.''
The drug maker employs about 12,600 people in central Indiana. Its worldwide employment stood at 40,300 as of March 31, down nearly 13 percent from 46,100 at the end of 2003.
Humalog ranked fourth among Lilly drugs with $1.5 billion (euro0.97 billion) in sales last year. Humulin notched $985 million (euro637.21 million), while Forteo took in $709 million (euro458.66 million).
Download
The Economic Times Business News App for the Latest News in Business, Sensex, Stock Market Updates & More.
The Economic Times Business News App for the Latest News in Business, Sensex, Stock Market Updates & More.
Download
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
ADVERTISEMENT
